Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

A recent groundbreaking study found that Glucagon-like peptide 1 receptor agonists (GLP1-RA) are effective in reducing venous ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a ...

The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...